DSM to Manufacture C. difficile Compound for U.K. Biotech Firm

DSM BioSolutions, part of the DSM Pharma cluster, says it has entered into an agreement with biotechnology company Novacta Biosystems (Welwyn Garden City, U.K.) for the process development and cGMP production of its C. difficile molecule, a new class of lantibiotic compounds. Financial terms of the deal were not disclosed. DSM has completed the process development and has commenced cGMP-manufacturing of the Novacta compound at its microbial fermentation biotech facility at Capua, Italy.  The product will initially be used for pre-clinical and phase I...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers